HCSG
Healthcare Services Group, Inc.
HCSG has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
HCSG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
HCSG's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HCSG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.02 | — |
| Cheap | 19x | $28.51 | +14% |
| Forward | 21x | $25.02 | — |
| Fair | 24x | $35.09 | +40% |
| Expensive | 35x | $52.32 | +109% |
Historical ranges are pointers, not guarantees.
HCSG's PE is in its cheap range at 17x. On analysts' estimates for next year's earnings, today's price would be 21x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over HCSG in the historical PE scenario, which offers more potential upside but is not a forecast.
HCSG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for HCSG, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over HCSG on the outlook, with more favorable valuation expectations.
HCSG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.18 | -20% |
| Q3 2026 | $1.48 | +179% |
| Q2 2026 | $1.71 | +1215% |
| Q1 2026 | $0.95 | +73% |
| Q4 2025 | $0.81 | +53% |
| Q3 2025 | $0.53 | -22% |
| Q2 2025 | $0.13 | -69% |
| Q1 2025 | $0.55 | -1.8% |
| Q4 2024 | $0.53 | +1.9% |
HCSG has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
HCSG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $479.6M | +3.3% |
| Q2 2026 | $470.8M | +2.7% |
| Q1 2026 | $462.8M | +3.4% |
| Q4 2025 | $466.7M | +6.6% |
| Q3 2025 | $464.3M | +8.5% |
| Q2 2025 | $458.5M | +7.6% |
| Q1 2025 | $447.7M | +5.7% |
| Q4 2024 | $437.8M | +3.3% |
HCSG's revenue has grown year over year for 11 quarters in a row: $480M last quarter, up 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | -5.3 points |
| Q2 2026 | 6.6% | +16 points |
| Q1 2026 | 7.5% | +2.1 points |
| Q4 2025 | 6.1% | +2.7 points |
| Q3 2025 | 12% | +8 points |
| Q2 2025 | -9.1% | -8.7 points |
| Q1 2025 | 5.3% | +0.3 points |
| Q4 2024 | 3.4% | -3.9 points |
HCSG has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over HCSG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
HCSG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.1M | -60% |
| Q2 2026 | $20.2M | -26% |
| Q1 2026 | $42.3M | +64% |
| Q4 2025 | $16M | -54% |
| Q3 2025 | $70M | +2302% |
| Q2 2025 | $27.4M | +83% |
| Q1 2025 | $25.8M | +$54M |
| Q4 2024 | $34.8M | -28% |
HCSG still generates free cash flow, though less than at its 2020 peak: $107M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over HCSG on cash flow, with more consistent year-over-year improvement.
HCSG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -526K shares |
| 1 year | -4.9% | -3.6M shares |
| 3 years | -6.7% | -5M shares |
| 5 years | -7.6% | -5.7M shares |
| Available history | -7% | -5.2M shares |
HCSG has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11.7M |
| Q2 2026 | $20.9M |
| Q1 2026 | $24M |
| Q4 2025 | $19.6M |
| Q3 2025 | $27.3M |
| Q2 2025 | $7.7M |
| Q1 2025 | $7M |
| Q4 2024 | $1M |
HCSG spent $76M buying back its own shares over the past year, up 77% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HCSG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -1.4x | Net Cash |
| Q4 2025 | -1.5x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -2.6x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
HCSG has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over HCSG on leverage, with a lower net debt burden relative to earnings.
HCSG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 70.5 | Neutral |
HCSG's weekly RSI is 61 (neutral) and its Stochastic is 71 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
HCSG PE vs Healthcare Sector
| Metric | HCSG | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 35% below |
| PE % | 6 | 29 | 23 pts below |
HCSG is trading at 17x earnings, a 35% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over HCSG on valuation relative to its sector.
HCSG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.9 | 9.5% above |
| 20 week MA | $22.9 | 9.4% above |
| 50 week MA | $21.3 | 17% above |
| 100 week MA | $17.5 | 43% above |
| 200 week MA | $14.7 | 71% above |
HCSG is in an uptrend: it's above all five of its weekly moving averages, and 71% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
HCSG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.3 | $27.1 | +11% |
| 2021 | $27.1 | $17.2 | -37% |
| 2022 | $17.2 | $12.2 | -29% |
| 2023 | $12.2 | $10.4 | -15% |
| 2024 | $10.4 | $11.5 | +11% |
| 2025 | $11.5 | $19.6 | +70% |
| 2026 YTD | $19.6 | $25.0 | +27% |
HCSG has finished lower in three of the last six years. It's up 27% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over HCSG on returns for 2026, with the stronger performance.